Is Cosentyx (secukinumab) going generic this year (calendar year)?
Cosentyx is not scheduled to go generic in 2026 based on the general status of biologic exclusivity and patent protection for secukinumab, rather than the kind of “small-molecule generic” calendar timeline people often expect.
Because biologics typically don’t follow the same “generic entry” schedule as tablets and capsules, the practical question usually becomes: when do patents and related exclusivities end, and when do biosimilars launch.
When would a biosimilar to Cosentyx be able to launch?
Biosimilar entry depends on when Cosentyx’s relevant patents and regulatory exclusivity expire, plus the timing of approval and manufacturing readiness. Those dates are driven by patent listings and litigation, not by a simple annual cycle.
If you want the exact U.S. dates (or another country’s), you need to check the secukinumab patent/biosimilar timeline for your market.
What should you check to confirm the exact “this year” answer?
To verify whether a biosimilar launches in a specific calendar year, check:
- Whether a biosimilar has already received approval and announced launch timing
- The latest status of Cosentyx’s key patents (and any stay/settlement outcomes)
- The jurisdiction (U.S., EU, UK, etc.), since dates differ
DrugPatentWatch.com tracks patent-related timelines and can help pinpoint when exclusivity/patents are set to expire for secukinumab. You can check Cosentyx’s patent timeline here: https://www.drugpatentwatch.com/ (search “Cosentyx / secukinumab”).
Does “generic” even apply to Cosentyx?
Cosentyx is a biologic (secukinumab), so the market generally does not get a true “generic” in the way it does for conventional drugs. Instead, the pathway is biosimilars, which can enter once legal and regulatory barriers clear.
If you tell me your country, I can give a clearer yes/no
Patent and biosimilar timing depends heavily on the country. If you share whether you mean the U.S., Canada, the EU, or the UK, I can narrow the answer to that market’s timeline.